 | Expert PracticeSM in Breast Cancer
7 February 2009 | Berlin, Germany
|
|---|
Meeting Information | On behalf of Dr Nadia Harbeck, meeting chairman, we are pleased to invite you to the Expert PracticeSM in Breast Cancer meeting in
Berlin, Germany, on 7 February 2009.
During this case-based meeting, leaders in the field discuss clinical issues encountered daily with participants in an interactive format.
Delegates will receive:
- Round trip economy air or train transportation.
- Hotel accommodation for 6 February. If no return flight available after the meeting, hotel accommodation will also be provided Saturday, 7 February.
|
Faculty | Chair:
Nadia Harbeck, MD, PhD – Germany
Speakers:
Ahmad Awada, MD, PhD – Belgium
Jacques Bonneterre, MD, PhD – France
Michael Gnant, MD, PhD – Austria
Paolo Pronzato, MD – Italy
Julie Doughty, MD, FRCS – United Kingdom
|
 Agenda |
| Friday, 6 February 2009 |
| 20.00 |
Reception followed by Buffet Dinner |
| Saturday, 7 February 2009 |
| 08.00 |
Breakfast |
| 09.00 |
Welcome and Introduction
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany
Bojana Pajk, MD, PRIME Oncology
Lee Lokey, MD, PRIME Oncology |
| 09.20 |
Case #1
HER-2 Amplified Early Breast Cancer: Choosing the Most Effective Adjuvant Therapy
Jacques Bonneterre, MD, Centre Oscar Lambret, Lille, France |
| 09.50 |
Case #2
Endocrine Responsive Early Breast Cancer: Decision Making for the Postmenopausal Patient
Julie Doughty, MD, University of Glasgow, Glasgow, UK
|
| 10.20 |
Case #3
Targeted Therapy for HER-2 Positive Metastatic Breast Cancer
Ahmad Awada, MD, PhD, Jules Bordet Institute, Brussels, Belgium
|
| 10.50 |
Break |
| 11.10 |
Case #4
Neoadjuvant Therapy in Endocrine Responsive HER-2 Negative Breast Cancer:
Multidisciplinary Management
Julie Doughty, MD, University of Glasgow, Glasgow, UK
Paolo Pronzato, MD, S. Andrea Hospital, La Spezia, Italy
Michael Gnant, MD, Medical University of Vienna, Vienna, Austria (commentary) |
|
11.50 |
Debate
In the Near Future Evidence from Randomized Clinical Trials Will
Support Inclusion of Zoledronic Acid as a Component of Adjuvant
Systemic Therapy for Early Breast Cancer
Pro: Michael Gnant, MD, Medical University of Vienna, Vienna, Austria
Contra: Paolo Pronzato, MD, S. Andrea Hospital, La Spezia, Italy |
| 12.20 |
Ask the Experts: An Interactive Discussion
|
| 12.40 |
Lunch |
| 13.40 |
Case #5
Breast Cancer Progression After Adjuvant Chemotherapy: What is the Best Approach?
Ahmad Awada, MD, PhD, Jules Bordet Institute, Brussels, Belgium |
| 14.10 |
Case #6
Breast Cancer Management During Pregnancy: A Difficult Challenge
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany |
| 14.40 |
Ask the Experts: An Interactive Discussion |
| 15.00 |
Concluding Remarks
Nadia Harbeck, MD, PhD, Technical University of Munich, Munich, Germany |
|

|